United Health Products Awaits FDA Response on Regulatory Compliance and Clinical Study Path

United Health Products, Inc. (OTCQB: UEEC) has provided an update on its ongoing discussions with the Food & Drug Administration (FDA) regarding the regulatory status of its Investigational Device Exemption (IDE) application. The company's IDE application was previously disallowed due to unresolved issues from a 2015 FDA Warning Letter, which cited violations of clinical procedures during a 2019 trial. In response, United Health Products submitted a detailed response to the FDA on April 14, 2025, addressing these violations, but as of now, the FDA has not issued a reply.

The resolution timeline for the FDA Warning Letter remains uncertain, prompting United Health Products to explore alternative pathways to advance its clinical study. The company has engaged with the FDA's IDE review team, separate from the group that issued the Warning Letter, to seek approval for a new IDE application. This effort includes discussions on potential solutions, such as identifying an alternative sponsor acceptable to the FDA to oversee the new clinical study. Under such an arrangement, United Health Products would retain exclusive rights to the data and analysis from the study, which would be incorporated into a revised Premarket Approval (PMA) application.

United Health Products has developed CelluSTAT Hemostatic Gauze, a patented, all-natural product designed to control mild to moderate bleeding, and is seeking FDA approval for use in the human surgical market. The company's proactive engagement with the FDA underscores the challenges and complexities inherent in navigating the regulatory landscape for medical devices. Further updates will be provided as discussions with the FDA progress. For more information, visit https://www.uhpcorp.com.